NCT04900844进行中（未招募）不适用
A Multicenter, Single-Arm, Pivotal Study to Evaluate the Safety and Efficacy of the CGuard™ Carotid Stent System When Used to Treat Symptomatic and Asymptomatic Carotid Artery Stenosis in Patients Undergoing Carotid Artery Stenting
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- InspireMD
- 入组人数
- 317
- 试验地点
- 34
- 主要终点
- Composite of DSMI through 30 days or ipsilateral stroke 31 - 365 days post-index procedure
研究概览
简要总结
The objective of this pivotal study is to evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS) to a performance goal developed from published CAS literature.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.
- •Subject is willing and able to take dual antiplatelet therapy for a minimum of 30 days.
- •Life expectancy ≥ 24 months from the date of the index procedure.
- •Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.
- •Subject has a modified Rankin Score of ≤ 2at the time of informed consent.
- •Subject is diagnosed with carotid artery disease treatable with carotid artery stenting and is considered high risk for carotid endarterectomy (CEA) as evidenced by:
- •Symptomatic carotid stenosis ≥ 50%. Symptomatic is defined as amaurosis fugax, transient ischemia attack (TIA) or stroke within the last 6 months ipsilateral to the side of the stenosis.
- •Asymptomatic carotid stenosis ≥ 80%
- •Co-Morbidity High Risk Conditions for CEA, i.e., meets one or more of the following criteria:
- •Age ≥ 70 (maximum 80 years)
- •CCS angina class 3-4 or unstable angina
- •Congestive Heart Failure (CHF) NYHA class III-IV
- •Left ventricular ejection fraction (LVEF) ≤ 35%
- •MI ≥ 72 hours and < 6 weeks pre-procedure
- •Multi-vessel CAD (≥ 2 vessels >70% stenosis) and history of angina
- •Chronic Obstructive Pulmonary Disease (COPD) with FEV1<50
- •Permanent contralateral cranial nerve injury/paralysis
- •Restenosis from previous carotid endarterectomy (CEA)
- •Planned coronary artery bypass grafting (CABG) or valve replacement surgery between 31-60 days after CAS
- •Abdominal aortic aneurysm repair or peripheral vascular surgery is planned between 31 to 60 days after CAS.
- •High Anatomical Risk for CEA, i.e., meets one or more of the following criteria:
- •Occlusion of the contralateral CCA or ICA.
- •Prior radiation treatment to the neck or a radical neck dissection.
- •Severe bilateral ICA stenosis requiring treatment.
- •Target lesion at or above the level of the jaw (C2) or below the clavicle.
- •Severe tandem lesions
- •Inability to extend the hear due to cervical disorders.
- •Laryngeal palsy or laryngectomy.
- •Prior head and neck surgery in the region of the carotid artery.
- •Tracheostomy or tracheostoma.
- •Spinal immobility of the neck.
- •Hostile neck or surgically inaccessible lesion.
- •Angiographic General Inclusion Criteria, i.e., meets all the following criteria:
- •Target lesion location at the carotid bifurcation and/or proximal internal carotid artery (ICA)
- •Vessel distal to target lesion can accommodate a distal embolic protection device (EPD), and EPD is compatible with CGuard™ device (refer to CGuard™ System IFU for specific EPDs).
- •Target vessel reference diameter at stent landing zone is 4.8 mm to 9.0 mm.
- •Target lesion length ≤ 36 mm, that can be covered by a single CGuard™ stent.
排除标准
- •Planned interventional procedure or surgery of the carotid, coronary or peripheral arteries within 30 days before or after the index carotid procedure.
- •Severe vascular anatomy that would preclude safe sheath insertion, deliverability of stent or embolic protection device.
- •Type III or bovine aortic arch.
- •Total occlusion of the target vessel.
- •Presence of "String sign" of the target lesion.
- •In-tandem lesions with >= 50% or >= 80% diameter stenosis for symptomatic or asymptomatic patients, respectively, which cannot be covered by a single CGuard™ stent.
- •History of bleeding diatheses or coagulopathy or inability to accept blood transfusions.
- •Bilateral carotid stenosis requiring treatment on both sides within 30 days prior to or following planned index procedure.
- •Subject is on renal replacement therapy or has Stage 4 or 5 Chronic Kidney Disease (CKD).
- •Known reason for potential stroke other than carotid artery stenosis, including history of atrial fibrillation or other sources of thromboemboli within the past 12 months.
- •History of thrombophilia.
- •Known sensitivity or allergy to nitinol, titanium, heparin, aspirin or other anticoagulant/ antiplatelet therapies.
- •Contrast media sensitivity or allergy that cannot be pre-treated.
- •Previous stent placement in the target vessel.
- •Evolving stroke or intracranial hemorrhage, or history of previous intracranial hemorrhage or brain surgery within the past 12 months.
- •Major neurologic deficit with NIHSS of ≥
- •Dementia or other neurologic condition confounding the neurologic assessment.
- •Clinical condition that, in the opinion of the investigator, makes endovascular therapy impossible or hazardous.
- •Subject previously enrolled in this clinical trial.
- •Possible / probable non-compliance of subject with protocol required follow up or medication.
- •Subject is currently participating in another clinical trial that has not completed its primary endpoint assessment or would confound this C-GUARDIANS Pivotal IDE Clinical Study.
- •SARS-CoV2 (COVID-19) active infection.
结局指标
主要结局
Composite of DSMI through 30 days or ipsilateral stroke 31 - 365 days post-index procedure
时间窗: From index procedure to 1 year follow up
The primary endpoint is the composite of the following: * Incidence of the following Major Adverse Events: Death (allcause mortality), all Stroke, and Myocardial Infarction (DSMI) through 30-days post-index procedure, based on Clinical Events Committee (CEC) adjudication OR * Ipsilateral stroke from 31-365 day follow-up, based on Clinical Events Committee (CEC) adjudication.
次要结局
- Incidence of major ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.(From index procedure to 3 years follow up)
- Composite of Ipsilateral stroke, stent thrombosis, cardiovascular death or other device related clinical events(From index procedure to 3 years follow up)
- Incidence of DSMI through discharge, 30 days, 6 months, and yearly follow ups till 3 years(From index procedure to 3 years follow up)
- Incidence of particular components of DSMI through discharge, 30 days, 6 months, and yearly follow ups till 3 years(From index procedure to 3 years follow up)
- Incidence of ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.(From index procedure to 3 years follow up)
- Incidence of target lesion revascularization(At 1-, 2-, 3-year post-index procedure follow-up)
- Incidence of In-stent Restenosis (ISR) > 70% in ultrasound evaluation(At 1-, 2-, 3-year post-index procedure follow-up)
- Incidence of In-stent Restenosis (ISR) > 50% in ultrasound evaluation(At 1-, 2-, 3-year post-index procedure follow-up)
- Composite of DSMI through 30 days or ipsilateral stroke 31 - 365 days post-index procedure for subjects that adhere to antiplatelet pharmacology.(From index procedure to 1 year follow up)
研究者
研究点 (34)
Loading locations...
相似试验
招募中
不适用
A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization ApproachNCT06653387InspireMD50
撤回
不适用
Sacral Nerve Stimulation to Treat Urgency Urinary Incontinence With Wireless NeuromodulationUrinary Incontinence, UrgeNCT02434874Uro Medical Corporation
进行中（未招募）
不适用
Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery StenosisCarotid Artery StenosisNCT02657707Microvention-Terumo, Inc.295
已完成
4 期
A Single Center of Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery DiseaseHeart DiseaseBrain Vascular AccidentCarotid Artery DiseaseCarotid StenosisNCT00178672The University of Texas Health Science Center, Houston69
已完成
不适用
Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary LesionsCoronary Artery DiseaseNCT01092416Abbott Medical Devices443